NCT06556407Recruiting
Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis
Source: ClinicalTrials.gov · Last updated 26 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 5 Aug 2024
- Start date
- 4 Mar 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- NCT number
- NCT06556407
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 4 Mar 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior renal denervation procedure
- Anatomic or functional solitary kidney, kidney transplantation
Other illness
- Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements
- Endocrine hypertension other than obstructive sleep apnea
- Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit
- Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months
- Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)
Other
- Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient
- Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement
- Subject is pregnant, nursing, or intends to become pregnant
- Enrollment in another interventional research protocol.
Who the study is looking for
- Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg
- end-stage renal disease on chronic hemodialysis
- Stable hemodialysis regime for at least 3 months based on the decision of the treating physician
- Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.
- Individual is ≥ 18 years of age, male and female patients are included.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension Coordinator of this site? Confirm its status | Erlangen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.